Eli Lilly (LLY) received FDA approval for its GLP-1 pill, Foundayo, on April 1, marking a significant milestone for the company. While not the first GLP-1 pill on the market, Foundayo presents a substantial growth opportunity, particularly as it complements the existing injectable treatment, Zepbound, which has already generated billions in revenue. The approval could help Eli Lilly expand its customer base, especially among patients who prefer oral medications over injections.
The approval comes at a crucial time for Eli Lilly, whose stock has declined 13% this year despite impressive revenue growth of 45% last year, driven primarily by Zepbound and Mounjaro. With the stock trading at over 40 times trailing earnings, investor sentiment remains cautious due to high valuations. However, the potential for Foundayo to enhance revenue from the lucrative GLP-1 market could reignite interest among investors.
For market professionals, the key takeaway is that Foundayo’s approval could serve as a catalyst for Eli Lilly’s stock recovery, especially if it successfully captures a larger share of the patient population seeking convenient treatment options.
Source: fool.com